Saturday, October 4, 2008
This is to draw your kind attention towards the issue of blocking of import of 30 drugs and two major production facilities (in India) of Ranbaxy laboratories Limited by the U.S. Food and Drug Administration (FDA). This is not the first time that the FDA has issued warning letters to Ranbaxy, the largest pharmaceutical manufacturer which is a black spot on the Indian Pharmaceutical Industry as a whole. U.S. being one of the biggest makets for Indian pharma products, it is a case which requires immediate attention and action. The Indian government should establish regulatory authorities with very strict guidelines in place to meet the stringent norms in the U.S. so that the image of Indian pharmaceutical industry as a whole is not stained or else it is not long before other parties to Indian pharma products across the globe shall join the U.S. in the queue for issuing us warning letters.